Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

Timothy H J Florin
Med J Aust 2004; 180 (6): . || doi: 10.5694/j.1326-5377.2004.tb05938.x
Published online: 15 March 2004

Timothy H J Florin

  • Department of Medicine, University of Queensland, Mater Health Services’ Adult Hospital, South Brisbane, QLD 4101.


Competing interests:

The author is a co-investigator on several clinical trials, including a Pharmacia-sponsored randomised placebo-controlled trial of anti-paratuberculosis treatment for patients with active Crohn’s disease.

  • 1. Kerr S, Mant A, Horn F, et al. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 2003; 179: 403-407. <eMJA full text>
  • 2. MacDonald T, Morant S, Goldstein J, et al. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003; 52: 1265-1270.
  • 3. Dowden J. Coax, COX and cola [editorial]. Med J Aust 2003; 179: 397-398. <eMJA full text>
  • 4. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
  • 5. Solomon D, Glynn R, Bohn R, et al. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol 2003; 30: 792-798.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.